Skip to main content

Advertisement

Fig. 5 | Molecular Cancer

Fig. 5

From: ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis

Fig. 5

Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (a) Experimental design and Therapeutic protocol for tail vein injection model (n = 5/group). (b) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (c) Gross appearance and histologic characteristics of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (d) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at the 7th weeks. (e) Histologic characteristics of bone and lung lesions in a representative mouse. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (f-g) Expression profiling of key components in Notch signaling pathways, including activated Notch1, ADAM17 and downstream MMPs, was substantially downregulated by SMI. *p < 0.05; **p < 0.01

Back to article page